Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control Trial

Study point of contact

Laila P Asonto
+966 55 458 6033
[email protected]
Mohammed SS Alshahrani, MD
+966 55 696 6663
[email protected]

Locations

1 Saudi Arabia site

Age

18 to 60 Years

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Drug

Other

Compensation

Unknown

About the study

Investigators hypothesize that administration of ketamine for pain relief in sickle cell
patients with vaso-occlusive crisis early on will lead to a more rapid improvement in pain
score and less narcotic requirement.

participation requirements

– Known diagnosis of SCD based on sickle cell tests and hemoglobin electrophoresis.

– Age 18 to 60 years

– Acute onset of painful crises, defined as having an onset within 7 days

participation restrictions

– Pregnancy

– Breast-feeding

– Altered mental status

– Body mass index greater than 40 kg/m2

– Patients with significant neurological disease

– Seizures

– Acute head injury

– Acute eye injury

– Patients with high intra-cranial tension

– Patients with known psychiatric disorders

– Patients with significant cardiac diseases

– Arrhythmias

– Patients with significant pulmonary diseases rather than acute chest syndrome

– Patients with significant renal disease (BUN/creatinine ratio < 25) - Patients with significant hepatic disease (Child Pugh class B or C) - Patients with significant endocrine disease - Known allergy to phencyclidine derivatives - Known allergy to ketamine - Known allergy to morphine - Sepsis - Septic shock - Patients required circulatory support - Patients required ventilatory supports - Alcohol abuse - Drug abuse - Patients with chronic pain status unrelated to SCD - Patients receiving anti-convulsant medications - Patients receiving anti-psychiatric medications. - Patients with communication barriers.

Locations

  • Dammam, Eastern, Saudi Arabia, Imam Abdulrahman Bin Faisal University, 31952 [Recruiting]